CASE REPORT

Eccrine Squamous Syringometaplasia Associated with Pelubiprofen Therapy

Joon Won Huh, Mingyul Jo, Jisook Yoo, Min Soo Kim, Kwang-Hyun Choi, Hyang-Joon Park, Mihn-Sook Jue

Department of Dermatology, Veterans Health Service Medical Center, Seoul, Korea

Eccrine squamous syringometaplasia (ESS) is a histologically distinctive skin eruption occurring predominantly in acral or intertriginous areas presenting as erythematous macules, papules or patches. The etiology of ESS remains unclear, but it is usually reported in patients receiving chemotherapy for various malignant neoplasms. To date, only two cases of ESS associated with non-steroidal anti-inflammatory drugs (NSAIDs), which has distinctive clinical features and pathogenesis, have been reported in the literature. Herein, we report a rare and interesting case of ESS associated with pelubiprofen, a recently developed NSAID, which appeared after pelubiprofen therapy and resolved spontaneously after discontinuing the medication. (Ann Dermatol 29(3) 334∼336, 2017)

Keywords
Eccrine squamous syringometaplasia, Metaplasia, Pelubiprofen, Phototoxicity

INTRODUCTION

Metaplasia is a process in which one cell type is transformed into another in an adaptive cellular mechanism in response to various stimuli. One of the common metaplasia in the skin is eccrine squamous syringometaplasia (ESS). ESS is histologically defined as metaplasia of the normal eccrine duct epithelium into two or more layers of squamous epithelial cells. It has been described in patients receiving chemotherapeutic agents for various malignant neoplasms, however, several infectious, neoplastic and inflammatory skin diseases have been found to induce ESS as well. To date, there has been only two reported cases of ESS associated with non-steroidal anti-inflammatory drugs (NSAIDs) in the literature. Herein, an unusual case of ESS associated with pelubiprofen, a recently developed NSAID, is presented.

CASE REPORT

An 83-year-old woman presented with multiple erythematous papules on the neck, forehead and hair line of scalp, which abruptly appeared and grew in size (Fig. 1). The lesion was mildly pruritic and lasted for 10 days. She underwent a surgical repair of femur neck fracture 15 days prior, and pelubiprofen was administered 5 days before skin eruption. She had no other general symptoms such as fever, chills, or malaise and no other remarkable medical history except hypertension with calcium channel blocker since 2009. Biopsy specimens were taken from the forehead and neck lesions with the impression of syringoma, and histopathologic evaluation showed numerous tubular structures and cellular infiltrations in the superficial dermis. The structures consisted of several layers of cells with uniform ductal epithelial proliferation and somewhat large squamous cells with round or oval nuclei and abundant eosinophilic cytoplasm with neither mitosis nor atypia. Relatively sparse inflammatory infiltrates containing lymphocytes, histiocytes, and a few neutrophils were noted...
Fig. 1. Multiple scattered erythematous papules on the forehead (A) and neck (B).

Fig. 2. (A) Biopsy specimen from the neck shows numerous tubular structures and cellular infiltrations on the upper dermis (H&E, ×100). (B) Squamous syringometaplasia (arrows) on the neck (H&E, ×400).

Fig. 3. At the 4-weeks follow-up, all lesions resolved spontaneously on the forehead (A) and neck (B).
around and within ductal structures (Fig 2). These histopathological changes were consistent with ESS. Pelubiprofen therapy was discontinued immediately, and all the lesions resolved spontaneously over the following 4 weeks (Fig. 3).

**DISCUSSION**

ESS has been described in association with various conditions and drugs, particularly in patients receiving chemotherapy. It typically presents as multiple, pruritic, erythematous papules, plaques, or vesicles usually on the axillae and groin. Histological features of ESS associated with chemotherapy show both typical findings of ESS and epidermal changes such as epidermal dystrophy, neutrophil eccrine hidradenitis, and necrosis of eccrine ducts. Although the pathogenesis of ESS remains unclear, it might represent a nonspecific reaction by damaged epithelial dermal ducts. In cases associated with drugs, the concentration and excretion of drugs in the eccrine duct are believed to trigger the toxic reaction in the ductal epithelium. This can be explained by the localization of these lesions in areas rich in eccrine glands.

In 1987, two cases of ESS associated with benoxaprofen, one of NSAIDs which was withdrawn from the market in 1982 after a few reports of fatal cholestatic hepatitis, were published in the literature. Present case is the first case of ESS induced by pelubiprofen. Pelubiprofen is a propionic acid-derived NSAID that is related both structurally and pharmacologically to ibuprofen. The Korean Ministry of Food and Drug Safety approved pelubiprofen for relieving the symptoms of osteoarthritis in 2007 and approved expanded indications for the relief of back pain in 2010. In these three cases of NSAIDs-associated ESS including present case, in contrast to chemotherapy-associated ESS, the lesions were distributed in sun-exposed areas such as face and neck, but not flexural areas, and epidermal changes such as erosion or necrosis were not observed, which implies that the reaction was not due to non-specific toxic damage of medication. Several NSAIDs are known to have phototoxic reaction. Among these NSAIDs classes, propionic acid-derivatives such as ibuprofen, ketoprofen, benoxaprofen and pelubiprofen are the most potent phototoxic agents. Lerner et al. postulated that benoxaprofen is secreted in sweat, causing selectively elevated drug levels in eccrine keratinocytes and hence, increased phototoxicity of these cells. Our case supports this postulation that NSAIDs-associated ESS is due to metaplasia possibly caused by phototoxic mechanism.

In conclusion, this is the third case of ESS associated with NSAIDs. We suggest that the pathogenesis of NSAIDs-associated ESS is a phototoxic reaction and although there had not been many reports of phototoxicity, clinicians should be aware that frequently prescribed NSAIDs, in particular derivatives of propionic acids, can induce phototoxic reaction, ESS, as an unusual clinical presentation.

**CONFLICTS OF INTEREST**

The authors have nothing to disclose.

**REFERENCES**

1. King DT, Barr RJ. Syringometaplasia: mucinous and squamous variants. J Cutan Pathol 1979;6:284-291.
2. Kim J, Kim SH, Lee MG, Chung KY, Kim DS. Eccrine squamous syringometaplasia of underlying syringoma associated with Tegafur/Gimeracil/Oteracil (TS-1). Acta Derm Venereol 2015;95:999-1000.
3. Martorell-Calatayud A, Sanmartin O, Botella-Estrada R, Balmer NN, Serra-Guillén C, Gomez-Moyano E, et al. Chemotherapy-related bilateral dermatitis associated with eccrine squamous syringometaplasia: reappraisal of epidemiological, clinical, and pathological features. J Am Acad Dermatol 2011;64:1092-1103.
4. Lerner TH, Barr RJ, Dolezal JF, Stagnone JJ. Syringomatous hyperplasia and eccrine squamous syringometaplasia associated with benoxaprofen therapy. Arch Dermatol 1987;123:1202-1204.
5. Gallo E, Llamas-Velasco M, Navarro R, Fraga J, Garcia-Diez A. Eccrine squamous syringometaplasia secondary to cutaneous extravasation of docetaxel: report of three cases. J Cutan Pathol 2013;40:326-329.
6. Moreno de Vega MJ, Dauden E, Abajo P, Bartolome B, Fraga J, Garcia-Diez A. Skin necrosis from extravasation of vinorelbine. J Eur Acad Dermatol Venereol 2002;16:488-490.
7. Valks R. Siringometaplasia escamosa ecrina. Actas Dermosifiliogr 2001;92:13-24.
8. El-Fidawi G, Akel R, Abbas O. Eccrine squamous syringometaplasia in a patient with plaque-type morphea. J Cutan Pathol 2014;41:548-549.
9. Han KD, Oh CW, Yoon TJ, Kim TH. A case of phototoxicity due to hydrochlorothiazide. Ann Dermatol 1998;10:289-292.
10. Ljunggren B. Propionic acid-derived non-steroidal anti-inflammatory drugs are phototoxic in vitro. Photodermatol 1985;2:3-9.